Oppenheimer Asset Management Inc. Purchases Shares of 9,498 Illumina, Inc. $ILMN

Oppenheimer Asset Management Inc. purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 9,498 shares of the life sciences company’s stock, valued at approximately $1,670,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Elyxium Wealth LLC acquired a new position in shares of Illumina in the 4th quarter valued at about $25,000. TD Waterhouse Canada Inc. acquired a new stake in Illumina during the 4th quarter worth approximately $26,000. Laurel Wealth Advisors LLC purchased a new position in Illumina in the fourth quarter valued at approximately $26,000. Activest Wealth Management raised its holdings in Illumina by 671.9% in the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after buying an additional 215 shares during the period. Finally, Quarry LP purchased a new position in Illumina in the third quarter valued at approximately $32,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ILMN. Citigroup boosted their price objective on shares of Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research note on Monday, August 3rd. Weiss Ratings raised shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. JPMorgan Chase & Co. lifted their target price on shares of Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $215.00 price target on shares of Illumina in a research report on Friday, July 31st. Finally, Piper Sandler reiterated an “overweight” rating and issued a $225.00 price target (up from $200.00) on shares of Illumina in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $188.40.

Insider Activity

In other news, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the sale, the senior vice president directly owned 21,259 shares in the company, valued at $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 500 shares of Illumina stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $80,000.00. Following the sale, the chief accounting officer directly owned 14,446 shares in the company, valued at approximately $2,311,360. The trade was a 3.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,415,351 shares of company stock valued at $255,966,311 in the last 90 days. Company insiders own 2.90% of the company’s stock.

Illumina Price Performance

NASDAQ ILMN opened at $190.89 on Monday. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $207.00. The business has a 50 day moving average price of $183.78 and a two-hundred day moving average price of $150.54. The stock has a market cap of $28.82 billion, a PE ratio of 35.61, a P/E/G ratio of 2.69 and a beta of 1.44.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the firm posted $1.19 earnings per share. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts predict that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.